%D9%85%D9%8A%D8%B3%D9%86%D8%A7%D9%85%D8%B3%D9%86%D8%A7MesnaMesnaMesnaMesna%D9%85%D8%B3%D9%86%D8%A7MesnaMesna%D7%9E%D7%A1%D7%A0%D7%94_(%D7%AA%D7%A8%D7%95%D7%A4%D7%94)%D5%84%D5%A5%D5%BD%D5%B6%D5%A1Mesna%E3%83%A1%E3%82%B9%E3%83%8A%E0%B4%AE%E0%B5%86%E0%B4%B8%E0%B5%8D%E0%B4%A8Mesna%E0%AC%AE%E0%AD%87%E0%AC%B8%E0%AC%A8%E0%AC%BEMesnaMesnaMesnaMesnaMesnaMesna%D0%9C%D0%B5%D1%81%D0%BD%D0%B0MesnaQ424997%E7%BE%8E%E5%8F%B8%E9%92%A0
about
P3781
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerA Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsR-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaAuto Transplant for High Risk or Relapsed Solid or CNS TumorsTreatment of Natural Killer/T Cell Lymphoma-Ⅲ/ⅣTreatment of Natural Killer/T Cell Lymphoma-I/IIPhase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCLLiver Transplantation With Tregs at UCSFCombination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue SarcomaCombination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's LymphomaCombination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCombination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced NeuroblastomaChemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic LeukemiaLow-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic OsteosarcomaFosaprepitant in Patients Receiving Ifosfamide-based RegimenAutologous Stem Cell Systemic Sclerosis Immune Suppression TrialHyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic LeukemiaChemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's LymphomasIovance Alliance: LN-145 Across Multiple Tumor TypesUmbilical Cord Blood Transplantation From Unrelated DonorsNK Cells to Prevent Disease Relapse for Patients High Risk Myeloid MalignanciesA Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue SarcomaUmbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesRandomized Double Cord Blood Transplant StudyHyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic LeukemiaTandem Auto-Allo Transplant for LymphomaPanobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin LymphomaAllogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesVinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer PatientsHaploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory NeuroblastomaVinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung CancerThiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk MalignanciesEffects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft ToleranceStudy to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue SarcomaCombined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative RegimenNilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
P4844
Q58407406-9fd4ba36-4326-c6b1-9ca9-8231ee4969e6Q61700075-F8B21E34-F308-4F60-A1D1-B866DB381508Q61914887-1A83A8E0-ECBF-482E-8451-934E974F3D70Q61921040-0A7BBF17-5E60-4DD9-BDBE-62F5F71A6E84Q61957088-544AA346-D6D0-44BF-A838-8D2193165097Q61957610-4E91BFD7-48A2-4165-9002-A13F813859F9Q61957611-D97EAAD9-0F51-4947-8741-BC61182FCFE8Q61980045-51E4AC8B-F4DA-4CDB-A4C5-AE1E7ED0A920Q62025115-BF006BFC-A2D5-4300-B5B8-C9EDB22E0827Q62110529-070005C1-2903-4866-A6DC-0A04220123C8Q62110545-7EA6F031-12CD-47B7-986A-21957FB51E6FQ62110587-8EED2A63-E1D2-4793-8988-AF6E12D706D8Q62110672-AF1BA559-7659-448F-8E4E-4CAD2149A6EEQ62111120-3AFE8237-CC0B-4BCD-B8FD-B15CC25251D6Q62817251-EC3DB602-45B4-4970-8EF4-B8DE7F1461B7Q63062537-4D58432F-DEB7-46DD-A4BA-A83C4F258CC1Q63320923-4C52EBA1-B25F-495B-B96D-E03EBE3CE689Q63321630-0F9E1BC3-6455-4062-BEA0-F73B2E975F73Q63334571-7519D30F-0133-458E-A80B-684589378DF2Q63337568-09B5FD78-4DFC-4921-AC33-F6BB6A2AF638Q63338137-6EEC898D-1A2E-48EA-96C4-0A6961DD2004Q63401035-6537D7DE-F652-40FC-B6EC-81D10DA8BFB1Q63571504-DA4D9F77-25B5-44F4-B7C5-5AAC11B0F177Q63575198-7471ADEB-1BC5-4103-B4D2-9B2F27F35D9CQ63575500-84BF2647-8EEB-4E48-86F1-A33B8674CECBQ63576708-84628E32-EC5D-4EC0-8945-F70236BE2323Q63577593-FDF19577-9BCF-43E1-BD3B-115358E4FF66Q63807825-A0382DFE-E2EF-41D8-B94D-7E8FE26B99E8Q63828947-9CC682B0-9CA4-4BFA-A6C8-4C0DC436527EQ63831998-B25DE359-C8A7-45CE-B3C0-2972CE3D4A39Q63838240-0F82F1C3-89DB-45D1-9F6A-807C58E23A36Q63841261-B59C3DF5-00A9-47BB-B3BB-81DC9E4F7311Q64043386-095A5B97-408A-4D7D-AA52-49B3D61C718EQ64071010-526E95DA-DA05-4A69-8F6A-7BF7E130E94FQ64123673-465AAFC2-0A0B-4C9D-BD96-7E7DDA68D7BAQ64151363-21434C53-1869-485E-AE11-0ABC8C0F872FQ64349424-08CD93BC-0D98-4B04-9D70-4E39648EFF8EQ64603077-86A66DFF-2868-4D90-BCEE-E10ABDB77800Q64609717-D4E88BD9-92F5-4260-A764-4364D60AC7A7Q64641933-CEC52440-7BD4-4C4E-B79C-525B2CD95AC9
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Mesna
@cs
Mesna
@de
Mesna
@en-ca
Mesna
@en-gb
Mesna
@fi
Mesna
@nl
Mesna
@ro
Mesna
@sh
Mesna
@sl
Mesna
@vi
type
label
Mesna
@cs
Mesna
@de
Mesna
@en-ca
Mesna
@en-gb
Mesna
@fi
Mesna
@nl
Mesna
@ro
Mesna
@sh
Mesna
@sl
Mesna
@vi
altLabel
19767-45-4
@pt-br
2-mercaptoetanossulfonato de sódio
@pt-br
C2H5NaO3S2
@fr
C2H5NaO3S2
@pt-br
Mercaptoetansolfonato di sodio
@it
Mesna
@zh
Sodio mercaptoetansolfonato
@it
ମେସନେକ୍ସ
@or
巯乙磺酸钠
@zh
prefLabel
Mesna
@cs
Mesna
@de
Mesna
@en-ca
Mesna
@en-gb
Mesna
@fi
Mesna
@nl
Mesna
@ro
Mesna
@sh
Mesna
@sl
Mesna
@vi
P486
P592
P6366
P646
P661
P662
P683
P117
P2067
P2115
N0000147597
P231
19767-45-4
P232
P233
C(CS(=O)(=O)[O-])S.[Na+]
P234
1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1
P235
XOGTZOOQQBDUSI-UHFFFAOYSA-M
P2566
100.039.336